Tag: botulinum toxin
November 3, 2016
Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis
Revance Therapeutics, a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of... June 17, 2016
Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
VANCOUVER, BRITISH COLUMBIA–(Marketwired – June 17, 2016) – Response Biomedical Corp. (“Response” or the “Company”) (TSX:RBM)(OTC:RPBIF) announces the closing of... April 7, 2016
ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A
ALPHAEON Corporation today announced positive data from two Phase III clinical trials of its DWP-450 botulinum toxin type A neuromodulator... December 24, 2015